SwePub
Sök i LIBRIS databas

  Extended search

onr:"swepub:oai:DiVA.org:liu-133538"
 

Search: onr:"swepub:oai:DiVA.org:liu-133538" > Wild-Type and Non-W...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Wild-Type and Non-Wild-Type Mycobacterium tuberculosis MIC Distributions for the Novel Fluoroquinolone Antofloxacin Compared with Those for Ofloxacin, Levofloxacin, and Moxifloxacin

Yu, Xia (author)
Capital Medical University, Peoples R China
Wang, Guirong (author)
Capital Medical University, Peoples R China
Chen, Suting (author)
Capital Medical University, Peoples R China
show more...
Wei, Guomei (author)
Capital Medical University, Peoples R China
Shang, Yuanyuan (author)
Capital Medical University, Peoples R China
Dong, Lingling (author)
Capital Medical University, Peoples R China
Schön, Thomas (author)
Linköpings universitet,Avdelningen för mikrobiologi och molekylär medicin,Medicinska fakulteten,Kalmar County Hospital, Sweden
Moradigaravand, Danesh (author)
Wellcome Trust Sanger Institute, England
Parkhill, Julian (author)
Wellcome Trust Sanger Institute, England
Peacock, Sharon J. (author)
Wellcome Trust Sanger Institute, England; University of Cambridge, England; London School Hyg and Trop Med, England
Koser, Claudio U. (author)
University of Cambridge, England
Huang, Hairong (author)
Capital Medical University, Peoples R China
show less...
 (creator_code:org_t)
AMER SOC MICROBIOLOGY, 2016
2016
English.
In: Antimicrobial Agents and Chemotherapy. - : AMER SOC MICROBIOLOGY. - 0066-4804 .- 1098-6596. ; 60:9, s. 5232-5237
  • Journal article (peer-reviewed)
Abstract Subject headings
Close  
  • Antofloxacin (AFX) is a novel fluoroquinolone that has been approved in China for the treatment of infections caused by a variety of bacterial species. We investigated whether it could be repurposed for the treatment of tuberculosis by studying its in vitro activity. We determined the wild-type and non-wild-type MIC ranges for AFX as well as ofloxacin (OFX), levofloxacin (LFX), and moxifloxacin (MFX), using the microplate alamarBlue assay, of 126 clinical Mycobacterium tuberculosis strains from Beijing, China, of which 48 were OFX resistant on the basis of drug susceptibility testing on Lowenstein-Jensen medium. The MIC distributions were correlated with mutations in the quinolone resistance-determining regions of gyrA (Rv0006) and gyrB (Rv0005). Pharmacokinetic/pharmacodynamic (PK/PD) data for AFX were retrieved from the literature. AFX showed lower MIC levels than OFX but higher MIC levels than LFX and MFX on the basis of the tentative epidemiological cutoff values (ECOFFs) determined in this study. All strains with non-wild-type MICs for AFX harbored known resistance mutations that also resulted in non-wild-type MICs for LFX and MFX. Moreover, our data suggested that the current critical concentration of OFX for Lowenstein-Jensen medium that was recently revised by the World Health Organization might be too high, resulting in the misclassification of phenotypically non-wildtype strains with known resistance mutations as wild type. On the basis of our exploratory PK/PD calculations, the current dose of AFX is unlikely to be optimal for the treatment of tuberculosis, but higher doses could be effective.

Subject headings

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Infektionsmedicin (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Infectious Medicine (hsv//eng)

Publication and Content Type

ref (subject category)
art (subject category)

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view